Gallach M, Vergara M, Miquel M, Casas M, Sánchez-Delgado J, Dalmau B, Gil M, Rudi N, Parra I, López M, Dosal A, Moreno L, Valero O, Calvet X

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 524-531
Archivo PDF: 165.87 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

2. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63:199-236.

3. Vergara M, Gallach M, Dalmau B, Gil M, Miquel M, Rudi N, Gavarro A, et al. Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: a 5-year experience. Gastroenterol Hepatol 2008; 31: 274-9.

4. Bruguera M, Forns X. Hepatitis C in Spain. Med Clin (Barc) 2006; 127: 113-7.

5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

6. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

8. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9.

9. Carrion JA, Gonzalez-Colominas E, Garcia-Retortillo M, Canete N, Cirera I, Coll S, Giménez MD, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 2013; 59: 926-33.

10. Navines R, Castellvi P, Moreno-Espana J, Gimenez D, Udina M, Canizares S, Die-Quevedo C, et al. Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord 2012; 138: 343-51.

11. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Jr., Fried MW, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149: 649-59.

12. Deeks ED. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs 2015; 75: 1027-38.

13. Le Lan C, Guillygomarc’h A, Danielou H, Le Dreau G, Laine F, Vedeilhie C, Deugnier Y, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcoholdependent patients with ongoing abuse. J Hepatol 2012; 56: 334-40.

14. De Montjoye BB, Ferrand I, Sogni P, Podevin P. Management of psychological disorders in patients with chronic hepatitis C. Encephale 2006; 32: 198-203.

15. Golden J, Conroy RM, O’Dwyer AM. Reliability and validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory (Full and FastScreen scales) in detecting depression in persons with hepatitis C. J Affect Disord 2007; 100: 265-9.

16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.

17. Quintana JM, Padierna A, Esteban C, Arostegui I, Bilbao A, Ruiz I. Evaluation of the psychometric characteristics of the Spanish version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 2003; 107: 216-21.

18. Lobo A, Perez-Echeverria MJ, Artal J. Validity of the scaled version of the General Health Questionnaire (GHQ-28) in a Spanish population. Psychol Med 1986; 16: 135-40.

19. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-45.

20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.

21. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000; 31: 241-6.

22. Cabre Serres M, Rudi Sola N, Pontes Garcia C, Vergara Gomez M, Parra Uribe I, Gorgas Torner MQ. Multidisciplinary approach as a model for detection and monitoring of psichiatric morbidity in patients treated with interferon and ribavirin. Farm Hosp 2014; 38: 162-8.

23. Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis 2006; 38: 119-24.

24. Bini EJ. Singin’ the blues: the downside of hepatitis C virus treatment. Am J Gastroenterol 2007; 102: 2434-6.

25. Marino EL, Alvarez-Rubio L, Miro S, Modamio P, Banos F, Lastra CF, Alberdi-Leniz A. Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C. J Manag Care Pharm 2009; 15: 147-50.

26. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002; 36: S121-7.

27. Spooner LM. The critical need for pharmacist involvement in the management of patients with hepatitis C. J Manag Care Pharm 2009; 15: 151-3.

28. Walters-Smith N, Marshall SM. Opportunities and considerations for pharmacist intervention in the management of the chronic hepatitis C patient. J Manag Care Pharm 2009; 15: 417-9.

29. Pearlman BL. The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection. Curr Gastroenterol Rep 2011; 13: 78-86.

30. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55: 692-701.

31. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012; 56: 2039-50.